Jesus, who is this and what have you done with Gavin? We all want success in stem cells in both MSB and CYP of course, as unlike the vast majority of the population, we are well informed on the relief they might provide patients with miserable options under traditional standards of care, particularly evident in the rates of mortality in GvHD, which hopefully MSB gets FDA approved on soon and indeed 20% amputation rates in DFU's that Cymerus has clearly deomnstrated better efficacy in, albeit on an admittedly small sample size at present.
CYP Price at posting:
28.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)